Cancer Vaccines Market to hit US$ 14.96 Billion by 2033 | Top 5 Companies are Merck & Co., Inc., GlaxoSmithKline plc (GSK), and Dendreon Pharmaceuticals LLC

global cancer vaccines market reached US$ 8.82 Billion in 2023, with a rise of US$ 9.27 Billion in 2024 and is expected to reach US$ 14.96 Billion by 2033, growing at a CAGR of 5.5% during the forecast period 2025-2033.

United States Cancer Vaccines Market size in 2024: USD 3.0 B and projection to USD 9.32 B by 2031 with a CAGR of 4.2% (2024-2031)

By 2050, the global cancer burden is projected to surge by 77%, reaching 35 million new cases, driven by aging populations, population growth, and rising exposure to risks such as tobacco, alcohol, obesity, and air pollution. High-income countries are expected to see the largest rise, with around 4.8 million additional cases.

Preventive cancer vaccines are projected to account for 51.33% of the total cancer vaccines market share.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample//cancer-vaccines-market?kb

Latest Developments on Russian Cancer Vaccine Research and Approvals

✦ Russia has announced its oncolytic mRNA-based cancer vaccine, Enteromix, is ready for clinical use after showing 100% efficacy in preclinical studies and promising results in early-stage trials targeting colorectal cancer, glioblastoma, and melanoma.​

✦ The vaccine is personalized using AI to analyze molecular tumor characteristics and formulate the vaccine within a week, with plans for public availability awaiting regulatory approvals in Russia.​​

✦ The Russian government has prioritized cancer vaccine development with new regulatory pathways speeding personalized mRNA therapeutic approvals separate from traditional drug processes.​

✦ Indian patients and doctors are actively seeking participation in Enteromix trials due to promising results, though wider international regulatory approval is pending.

Latest M&A

Johnson & Johnson acquired Halda Therapeutics for $3.05 billion in November 2025, gaining access to a novel cancer cell death platform and an experimental prostate cancer vaccine (HLD-0915) in early clinical stages, broadening its oncology pipeline.

Merck is active with multiple acquisitions, including a $9.2 billion deal for Cidara Therapeutics which has promising antivirals and immunotherapies related to cancer and infectious diseases, potentially boosting cancer vaccine capabilities indirectly

Key Players:

✅ Moderna, Inc.
Specializing in mRNA-based personalized cancer vaccines.

✅ BioNTech SE
Leading mRNA immunotherapies and personalized cancer vaccine programs.

✅ F. Hoffmann-La Roche Ltd (Genentech)
Strong pipeline in therapeutic cancer vaccines and immuno-oncology.

✅ AstraZeneca plc
Developing combination cancer vaccine therapies with checkpoint inhibitors.

✅ Merck & Co., Inc.
Investing heavily in clinical-stage cancer vaccine candidates.

✅ GSK plc
Active in HPV and therapeutic oncology vaccine research.

✅ Eli Lilly and Company
Expanding oncology pipeline with targeted and immune-based therapies.

✅ Inovio Pharmaceuticals, Inc.
DNA-based cancer vaccines and immunotherapy solutions.

✅ ImmunoGen, Inc.
Developing antibody-drug conjugates and immunotherapeutic vaccine approaches.

✅ Advaxis, Inc.
Clinical-stage biotech focused on Lm-based immunotherapies.

Emerging Players

The emerging players in the cancer vaccines market include Candel Therapeutics, Elicio Therapeutics, Evaxion, Imugene, Nouscom, OSE Immunotherapeutics, Scancell, and Takis

Key Industry Developments

In March 2025, Everest Medicines delivered the first dose of its personalized mRNA cancer vaccine, EVM16, in the initial human trial EVM16CX01. Conducted at Peking University Cancer Hospital in China, the study will evaluate the vaccine's immunogenicity, safety, preliminary efficacy, and tolerability in patients with advanced or recurrent solid tumors.

Growth Forecast Projection:

The Global Cancer Vaccines Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

FDA Approvals

The FDA fully approved TIVDAK (tisotumab vedotin-tftv) in late 2024 for previously treated recurrent or metastatic cervical cancer, an antibody-drug conjugate that acts as a cancer vaccine by targeting tumor cells with minimal systemic impact

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cancer-vaccines-market?kb

Key Segmentation:

By Type: (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines)

By Cancer Type: (Prostate Cancer, Cervical Cancer, Lung Cancer, Bladder Cancer, Others)

By Technology: (Protein-based, Nucleic acid-based (DNA, RNA/mRNA), Whole-cell, Viral vector, Dendritic cell, Recombinant/adjuvant.)

By Route of Administration: Intramuscular, Intravenous, Others)

By End User: (Hospitals, Clinics, Cancer Treatment Centers, Government Entities, Other)

Supply Chain Challenges and Innovations

✅ Cold chain logistics remain a critical element given the need for ultra-low temperature storage (e.g., -70°C for mRNA vaccines), prompting investment in advanced refrigeration and transport solutions worldwide.​

✅ Just-in-time manufacturing and regional production hubs are increasingly favored to reduce lead times and mitigate global supply chain vulnerabilities highlighted during the COVID-19 pandemic.​

✅ Advanced digital supply chain platforms, employing AI and blockchain, are being deployed to track vaccine manufacturing, delivery, and administration securely and transparently across jurisdictions.​

Access and Distribution Considerations

✅ Distribution strategies emphasize equitable access, particularly in low- and middle-income countries, through tiered pricing, voluntary licensing, and collaborative global procurement frameworks such as those facilitated by Gavi and WHO.​

✅ Personalized cancer vaccines require coordinated supply chains that link diagnostics, manufacturing sites, and clinical centers efficiently to ensure timely and precise delivery to patients.

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Clinical Trials

✅ Over 70 personalized mRNA cancer vaccine trials are ongoing, focusing on neoadjuvant/adjuvant settings in melanoma, lung cancer, and other solid tumors. Moderna's mRNA-4359 candidate targeting checkpoint inhibition pathways entered early Phase 2 trials in NSCLC and melanoma in 2025.

✅ Trials combining mRNA vaccines with checkpoint inhibitors and targeted therapies are advancing, showing promising immune response enhancements and disease control improvements.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize//cancer-vaccines-market?kb

Drugs and Pipeline

Leading candidates include personalized neoantigen vaccines, T-cell epitope-targeting platforms like Tedopi (OSE2101) for NSCLC, and peptide-based vaccines for colorectal, glioblastoma, and melanoma cancers.

ImmunityBio is advancing multi-antigen targeted cancer vaccines with promising preclinical data and ongoing clinical trials in pancreatic and other tumors

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry//cancer-vaccines-market?kb

Active Phase 2 and 3 Clinical Trials of Cancer Vaccines

✅ Numerous Phase 2 and 3 trials are active globally involving mRNA-based cancer vaccines targeting various cancers like melanoma, non-small cell lung cancer (NSCLC), glioblastoma, and colorectal cancer. Key vaccine candidates include Moderna's mRNA-4157 (V940) in combination with pembrolizumab, showing sustained clinical benefit in melanoma and NSCLC, now enrolling in extensive Phase 3 trials.

✅ IO Biotech's IDO and PD-L1 targeting peptide vaccine, granted FDA Breakthrough Therapy designation, is in Phase 3 trials for melanoma and Phase 2 trials for several others including bladder and head & neck cancers.

✅ Several Phase 2/3 trials focus on personalized neoantigen vaccines, combining with checkpoint inhibitors, aimed at improving immune responses and long-term tumor control across solid tumors

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.